Research and Development

In December 2010, Jeffrey Kindler, the chief executive of Pfizer suddenly announced his departure from the company.His abrupt exit made …

Janssen has signed a deal with Forma Therapeutics to discover, and develop drugs that target tumour metabolism mechanisms.Forma focuses on …

Aegate’s board of directors have announced that the previous director general of the ABPI has joined the company as a …

The University of California, San Francisco (UCSF) and Sanofi are to launch a new collaboration in diabetes research, focusing on …

GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …

Contract research organisation ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to be the sole global provider of …

An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …

Bristol-Myers Squibb will acquire virology specialist Inhibitex for $2.5 billion, expanding its infectious disease portfolio. Bristol-Myers Squibb will acquire the …

Celgene has appointed former Pfizer man Dr David Gillen as its new UK and Ireland medical director. Gillen brings much …

A round up of some of the key themes in pharma’s yearEUROPE IN CRISIS While the Eurozone has averted meltdown …

The current EU- eCTD v3.1 validation criteria came into force on 1st September 2011 for the technical validation for all …

A court in Argentina says GSK should be fined for irregularities in recruitment during a trial in which children died. …

Biogen has signed a new deal with drug discovery firm Isis for its spinal muscular atrophy drug ISIS-SMNRx. Biogen will pay …

AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …

Amsterdam Molecular Therapeutics has been granted an orphan drug designation for its gene therapy for haemophilia B.The FDA’s orphan designation …